Survival analysis showed COAD, LUSC, PAAD, and STAD patients accompanied by TXNL4B overexpression presented shorter overall survival duration, whereas patients with lower expression had longer survival duration (Figure 2B). Here, TXNL4B is linked to pancreatic adenocarcinoma.